Track topics on Twitter Track topics that are important to you
SODIUM CITRATE 4% W/V ANTICOAGULANT SOLUTION is intended for use only for the anticoagulation of whole blood as part of automated apheresis procedures. [See Dosage and Administration (2).]
SODIUM CITRATE 4% W/V ANTICOAGULANT SOLUTION USP is added to tubing sets during apheresis procedures. The solution is connected the tubing set in an apheresis collection. The recommended dose is determined by the apheresis device and metered into the tubing set by the apheresis device. It is not intended for direct intravenous infusion.
For instructions on the use of the solution with the apheresis device and tubing set, see the device operator's manual.
Directions for connecting the SODIUM CITRATE 4% W/V ANTICOAGULANT SOLUTION USP bag to the apheresis device.
At the prompt to connect anticoagulant to the apheresis device tubing set:
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever the solution and container permit.
250 mL SODIUM CITRATE 4% W/V ANTICOAGULANT SOLUTION USP is a sterile solution in a PVC bag. Each 100 mL contains: Sodium Citrate (dihydrate) 4.0 g; and 100 mL Water for Injection, (pH adjusted with citric acid).
DO NOT INFUSE SODIUM CITRATE 4% W/V ANTICOAGULANT SOLUTION USP DIRECTLY TO THE DONOR.
Citrate reactions or toxicity may occur with the infusion of blood products to patients and return of blood containing citrate anticoagulant to donors. The recipient of the blood containing citrate should be monitored for the signs and symptoms of citrate toxicity. The signs and symptoms of citrate toxicity begin with paresthesia, a "tingling" sensation around the mouth or in the extremities, followed by severe reactions that are characterized by hypotension and possible cardiac arrhythmia. Citrate toxicity may occur more frequently in patients who are hypothermic, have impaired liver or renal function, or have low calcium levels because of an underlying disease.
SODIUM CITRATE 4% W/V ANTICOAGULANT SOLUTION USP has not been adequately studied in controlled clinical trials with specific populations.
SODIUM CITRATE 4% W/V ANTICOAGULANT SOLUTION USP is designed to be metered by an apheresis device in apheresis procedures, to prevent platelet activation and coagulation as blood moves throughout the extracorporeal unit (tubing set) in an apheresis procedure.
The solution is sterile and non-pyrogenic, and it contains no bacteriostatic or antimicrobial agents.
The formulas of the active ingredients are provided in Table 1.
Each 100 mL of SODIUM CITRATE 4% W/V ANTICOAGULANT SOLUTION USP contains: Sodium Citrate (dihydrate) 4.0 g; and 100mL Water for Injection (pH adjusted with citric acid).
The PVC bag is not made with natural rubber latex.
The bag is made from a multilayered film. It contains materials that have been tested to demonstrate the suitability of the container for storing pharmaceutical solutions. The bag is nontoxic and biologically inert. The bag-solution unit is a closed system and is not dependent upon entry of external air during administration. The bag is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary.
|Ingredients||Molecular Formula||Molecular Weight|
|Sodium Citrate Dihydrate||C6H9Na3O9||294.10|
|Water for Injection||H2O||18.00|
SODIUM CITRATE 4% W/V ANTICOAGULANT SOLUTION USP acts as an extracorporeal anticoagulant by binding the free calcium in the blood. Calcium is a necessary co-factor to several steps in the clotting cascade. The following ingredients are key components of the solution:
This solution has no pharmacological effect.
SODIUM CITRATE 4% W/V ANTICOAGULANT SOLUTION USP is a clear solution supplied in sterile and non-pyrogenic PVC bags. The bags are packaged 30 bags per case.
|SIZE||CATALOG NUMBER||NDC NUMBER|
Up to 25 °C.Protect from freezing.
Issued: August 2017
Manufactured by Terumo BCT, Inc. Lakewood, CO 80215
Sodium Citrate 4% w/vAnticoagulant Solution USP
Catalog # 40881 30 x 250 mL units NDC 14537-881-25
For use only with automated apheresis procedures.
See apheresis device operator's manual for complete instructions.Read the package insert before application.Sterile. Non-pyrogenic. Sterilized with steam. Caution: Do not use unless the solution is clear and the container is intact.Single use container. Discard any unused product. Not for directintravenous infusion. Rx Only.
Recommended storage: Up to 25 °C.Protect from freezing.
Each 100 mL contains: Sodium Citrate Dihydrate 4.0 g Water for Injection to(pH adjusted with citric acid) 100 mL Approximate Millimoles: Sodium Citrate 13.8
Manufactured by Terumo BCT, Inc.10811 W. Collins Ave., Lakewood CO 80215, USA
Lot Expiry Date
Terumo BCT, Ltd
Haemonetics Anticoagulant Citrate Dextrose Solution
Anticoagulant Sodium Citrate Solution, USPCode 798-60
ACD-A Anticoagulant Citrate Dextrose Solution, Solution A, U.S.P., PN 9350, 30 mL NDC 23731-6051-3
Haemonetics Anticoagulant Sodium Citrate
This study intends to characterize the affect of sodium and potassium citrate in the diet on renal function.
Evidence that supports using certain concentration of trisodium citrate as a locking solution for hemodialysis catheters has not yet been established. Higher concentrations of trisodium ci...
Acetate-free citrate containing dialysate is expected to be clinically effective in maintaining hemodynamic stability during hemodialysis (HD). It has been demonstrated that citrate dialys...
This study will test the hypothesis that by slightly lowering the acidity of blood (or increasing the pH), dialysis patients utilize protein and amino acids more efficiently.
The aim of this study is to compare the efficacy depending on the order of the sequential combination method using sodium picosulfate and magnesium citrate (PMC) and PEG with ascorbic acid...
Sodium citrate has become the preferred anticoagulant used for apheresis collection and has been included in commercial platelet additive solutions (PASs) since PAS-II. It was suggested that citrate b...
This study aimed to maximise the amount of CO storage by indirect carbonation using paper sludge ash (PSA), which is an alkaline industrial waste. The properties of the following three types of solven...
This study reports the result of sodium citrate induced exopolymer extraction on the photocatalytic thin film (TiO) pretreatment efficiency of waste activated sludge (WAS). TiO is immobilized through ...
A sensitive assay for citrate was developed. Citrate was incubated with 50 μM Eu-tetracycline and the complex separated using capillary electrophoresis utilizing post-column laser-induced luminescen...
Limited reports are available on the role of 4% citrate as a locking solution for temporary dialysis catheters. Hence, the aim of this study is to investigate the role of 4% citrate vs. heparin 5,000 ...
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...
Cardiology is a specialty of internal medicine. Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...